The Venture Codex

Participated · Series A · Apr 2026

Vivacta is developing next-generation in vivo CAR-T therapies, with its lead program GT801 focused on hematologic malignancies and autoimmune diseases. Early clinical data reported at ASH 2025 indicated promising safety and efficacy signals for GT801. The company plans to use new financing to advance GT801 clinical trials, pursue regulatory submission and approval, expand its research team and platform, and drive global expansion. Vivacta describes its investor base as a mix of global industrial capital and specialist biotech investors, and raised over US$50 million in its Series A and Series A+ financings. After the financing, representatives from Loyal Valley Capital and DC Global Ventures joined the board, signaling investor engagement in governance and strategy.

Participated · Seed · Mar 2026

Excalipoint Therapeutics is a clinical-stage biotechnology company focused on discovering and developing T-cell engager (TCE) therapies for oncology and immunology indications. Its pipeline includes tri- and multi-specific antibody programs such as EXP011 (CTM012) targeting DLL3/CD3/4-1BB—entered Phase I/II with first patient dosed in October 2025—EXP012 (CTM013) targeting CDH17/CD3/4-1BB, and additional programs (EXP016, EXP017, EP101, EXP015) built on its TOPAbody, Immune Shield, and Pro-TCE platform technologies. The company is led by CEO Lei Fang and CFO Jielun Zhu. Following the $68.7M Seed raise, Excalipoint intends to use the funds to advance its proprietary platforms and progress its pipeline programs through clinical development.

Participated · Series A · Dec 2024

Qi Biodesign builds and commercializes a proprietary SEEDIT™ research platform that includes novel RNA‑guided nucleases, base editors, plant prime editors, and PrimeRoot™ editors for precise large DNA insertions and multiplex trait engineering. Its tools enable multiplex gene editing, fine‑tuning of gene expression, high‑throughput trait discovery, and acceleration of superior trait development for crops and synthetic biology applications. The company has achieved regulatory milestones, including two biosafety certificates from the China Ministry of Agriculture and Rural Affairs for high oleic acid soybean and powdery mildew‑resistant wheat, and an exemption from the U.S. Department of Agriculture for its high oleic acid soybean. Qi Biodesign is advancing additional traits—yield, herbicide tolerance, and quality improvements—through regulatory pipelines. The company plans to use new funding to enhance R&D, advance SEEDIT™, support product development, and build commercialization platforms to speed transition from research to market. Founded by genome‑editing scientists and industry executives, Qi Biodesign positions its platform to address food security and sustainable agriculture challenges.

Participated · Seed · Jun 2021

Float Foods is a Singapore-based startup that has developed OnlyEg, a legumes-based plant-based analogue of a whole chicken egg. OnlyEg is produced in two parts—a white and a yolk substitute—so it can be prepared similarly to real eggs and used in dishes like soft‑boiled eggs and sunny‑side‑ups. The company was founded by serial entrepreneur Vinita Choolani about one year ago and operates out of the Innovate360 foodtech incubator workspace. Float Foods is refining OnlyEg in the lab to enhance nutritional benefits and extend shelf life, and expects consumer availability in Singapore next year. It plans regional expansion into markets including China, India, and Indonesia, and is developing ancillary plant-based products—egg patties and shreds—for B2B sales later this year. Financially, the startup raised S$2.2 million in seed funding and previously secured an undisclosed grant from the Temasek Foundation.

Participated · Series B · Apr 2021

Hepagene Therapeutics Inc. is a clinical-stage drug discovery and development firm focused on therapies for liver diseases. Since its inception in 2016 the company has focused on indications including non-alcoholic steatohepatitis, chronic hepatitis B infection and cancer. The company said it will use the proceeds to support the clinical research of its pipeline candidates. It recently completed a $40 million Series B1 round. Investors in that round include Loyal Valley Capital, Oceanpine Capital and existing investor Apricot Capital. Loyal Valley Capital is described in the announcement as a ByteDance backer.